Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Retinal Degeneration: early-phase trial registry
8 of 18 indexed Retinal Degeneration trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 8 currently recruiting · #953 of 28,707 conditions by registered trial count
Retinal Degeneration: 18 US clinical trials tracked, 8 recruiting.
Retinal Degeneration is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is National Eye Institute (NEI), running 5 of these trials.
Enrollment posture brief
Registry condition retinal-degeneration
OPEN 8 | RECR 44% | LATE 1 | EARLY 7 | RANK #953 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Retinal Degeneration lists 8 open slots (44% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Retinal Degeneration on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Retinal Degeneration is recruiting below its size-band peers.
8 of 18 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Retinal Degeneration research.
National Eye Institute (NEI) accounts for 5 of 18 trials (27.8%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Retinal Degeneration trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 18 trials that report a genuine target (sentinel values excluded). 13 of those (72.2%) plan for fewer than 100 participants.
-
Retinal Degeneration splits between interventional and observational designs.
9 interventional and 9 observational studies make up this index (50% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
Cell Collection to Study Eye Diseases
National Eye Institute (NEI)
NCT01432847
Rod and Cone Mediated Function in Retinal Disease
National Eye Institute (NEI)
NCT02617966
Adaptive Optics Imaging of Outer Retinal Diseases
Food and Drug Administration (FDA)
NCT05355415
SGLT2 Inhibitors in Geographic Atrophy
Washington University School of Medicine
NCT07174687
Oral Metformin for Treatment of ABCA4 Retinopathy
National Eye Institute (NEI)
NCT04545736
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
BlueRock Therapeutics
NCT06789445
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
PYC Therapeutics
NCT06852963
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
PYC Therapeutics
NCT06455826
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
Complement Therapeutics
NCT05797896
Natural History of Eye Diseases Related to ABCA4 Mutations
National Eye Institute (NEI)
NCT01736293
Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F
Jaeb Center for Health Research
NCT04765345
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Nanoscope Therapeutics
NCT06162585
Molecular Genetics of Retinal Degenerations
National Eye Institute (NEI)
NCT00231010
A Multi-Center Study of Reading Rehabilitation in Macular Disease
US Department of Veterans Affairs
NCT00746668
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
Nanoscope Therapeutics
NCT04945772
Natural History Study of CEP290-Related Retinal Degeneration
Editas Medicine
NCT03396042
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
Pfizer
NCT01003691
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
Novartis Pharmaceuticals
NCT03954626
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Retinal Degeneration records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Retinal Degeneration trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Retinal Degeneration page
18 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Retinal Degeneration trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Eye Institute (NEI) sponsors the most Retinal Degeneration trials on record, review their full trial history before evaluating a specific study. See National Eye Institute (NEI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Retinal Degeneration condition card totals 18 registered trials; most-linked intervention VP-001; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.